Suvretta Capital Management LLC Acquires 1,253,901 Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)

Suvretta Capital Management LLC boosted its holdings in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) by 32.8% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,073,913 shares of the biopharmaceutical company’s stock after purchasing an additional 1,253,901 shares during the quarter. Suvretta Capital Management LLC owned 0.09% of Marinus Pharmaceuticals worth $8,930,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. increased its holdings in shares of Marinus Pharmaceuticals by 5.0% during the first quarter. Vanguard Group Inc. now owns 2,805,920 shares of the biopharmaceutical company’s stock worth $25,366,000 after purchasing an additional 132,689 shares during the period. abrdn plc grew its position in Marinus Pharmaceuticals by 146.1% during the third quarter. abrdn plc now owns 2,658,527 shares of the biopharmaceutical company’s stock worth $4,679,000 after buying an additional 1,578,329 shares in the last quarter. GSA Capital Partners LLP increased its stake in Marinus Pharmaceuticals by 409.4% during the 3rd quarter. GSA Capital Partners LLP now owns 1,016,634 shares of the biopharmaceutical company’s stock worth $1,789,000 after acquiring an additional 817,050 shares during the period. Acadian Asset Management LLC acquired a new position in Marinus Pharmaceuticals in the 2nd quarter valued at $813,000. Finally, Renaissance Technologies LLC bought a new stake in shares of Marinus Pharmaceuticals during the 2nd quarter valued at $727,000. Institutional investors and hedge funds own 98.80% of the company’s stock.

Marinus Pharmaceuticals Price Performance

NASDAQ MRNS opened at $0.32 on Friday. Marinus Pharmaceuticals, Inc. has a twelve month low of $0.26 and a twelve month high of $11.26. The business’s fifty day moving average is $1.01 and its 200 day moving average is $1.24.

Analyst Ratings Changes

A number of research analysts recently commented on MRNS shares. EF Hutton Acquisition Co. I upgraded Marinus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, September 30th. Truist Financial cut shares of Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 24th. StockNews.com assumed coverage on shares of Marinus Pharmaceuticals in a research report on Tuesday. They set a “hold” rating on the stock. LADENBURG THALM/SH SH downgraded shares of Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 14th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $4.00 target price on shares of Marinus Pharmaceuticals in a report on Thursday, November 14th. Nine analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Marinus Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $4.79.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.